Scientists have uncovered new evidence suggesting that damage to nerve cells in people with multiple sclerosis (MS) accumulates because the body’s natural mechanism for repairing the nerve coating   more »

To elucidate the role of central motor activation we hypothesized that patients with primary fatigue have impaired central motor function and increased fatigability as compared to secondary fatigued and non-fatigued   more »

The therapeutic goal for multiple sclerosis (MS) is to achieve a better long-term outcome. However, since available data come from short-term studies, it is important to review the evidence that current therapies   more »

UCSF researchers have identified a correlation between higher levels of glutamate, which occurs naturally in the brain as a byproduct of metabolism, and greater disease burden in multiple sclerosis patients. The study is the first to measure glutamate toxicity in the brain over time and   more »

In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a disease duration of 3 years or less to receive   more »

A statistical distribution describing the number of new enhancing lesions seen on MRI in patients with MS is of great importance for improving the statistical methodology of clinical trials using new enhancing   more »

Contrary to strong recommendations for high-dose intravenous corticosteroid treatment for relapses in multiple sclerosis (MS), uncertainty remains about most aspects of relapse management. Oral corticosteroids   more »

Demographic and neurological data were collected on 140 consecutive clinic attendees, and their lifetime and point prevalence’s of anxiety disorders were determined with the Structured Clinical Interview for DSM-IV disorders (SCID-IV). All subjects completed the self-report Hospital Anxiety   more »

Post-mortem studies demonstrate extensive grey matter demyelination in MS, both in the brain and in the spinal cord. However the clinical significance of these plaques is unclear, largely   more »

Scientists at the Complutense University of Madrid (UCM) have studied the effects of a drug that reduces the progression of a disease similar to Multiple Sclerosis in animals. This discovery represents another   more »

The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study. CUPID is a clinical trial which will evaluate whether   more »

Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system (CNS), which causes demyelination of axons. Experimental autoimmune encephalomyelitis (EAE) is a mouse model of MS that is induced   more »

One year of treatment with interferon beta-1a significantly improves the quality of life for individuals diagnosed with multiple sclerosis (MS), researchers reported here at the   more »

This study examined access to and use of neurologists among a USA National broad, sample of people with multiple sclerosis (MS); identified demographic, economic, and clinical factors associated with access and use; and examined differences in   more »

Inflammation-induced oxidative stress can lead to axonal degeneration, which is felt to be a major determinant of progressive neurological disability in Multiple Sclerosis (MS).   more »